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ABSTRACT 
STUDY TITLE: ESTIMATION OF SERUM AND SALIVA COTININE LEVELS IN 
ACTIVE SMOKERS AND NON SMOKERS 
Background and Objectives: Smoking is the single most cause of disability, and death 
affecting the World’s population today. Cotinine the major metabolite of nicotine is generally 
regarded as the best biomarker for monitoring tobacco exposure in both actively and 
passively exposed individuals. The aim of the study was to estimate and compare cotinine 
level in smokers and Non- smokers in saliva and serum by High profile liquid 
chromatography. 
Materials and methods: Serum and Saliva samples were collected. Chromatography was 
performed using an L-7100 pump, an L-7400 UV detector, an L-7200 auto sampler, an L-
7500 integrator and an 865-CO column oven. Cotinine was quantified by comparing the 
HPLC peak heights to those of authentic standard. 
Results: Study group showed higher serum and saliva cotinine levels than control group. 
Serum cotinine levels were significantly higher than saliva cotinine levels in study group. 
Serum and saliva cotinine levels in control group was not significant. 
Conclusion: Our study shows the importance of estimating cotinine levels for distinguishing 
tobacco users from non-users, for estimating the nicotine intake of tobacco users and for 
specifying the exposure of nonsmokers to second hand smoke. The use of High profile liquid 
chromatography with its superior resolving power is also recommended. However more 
studies are needed using High profile liquid chromatography to establish standardized values. 
Keywords: Cigarette smoke, Cotinine, High profile liquid chromatography 
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 Smoking is the single most cause of disability, and death affecting the 
World’s population today. The World Health Organization (WHO) reports that 
15 billion cigarettes are sold daily and that approximately a third of the global 
male adult population smokes as quoted by (WHO 2002). Globally, one in ten 
adults die from smoking and related diseases every day and the WHO states 
that if this current trend continues, by the year 2030, smoking will kill 
approximately one in six people as per (WHO 2020). Smoking is a global 
issue and despite progress in reducing smoking prevalence, it is still a huge 
problem affecting many countries. 
 The Global Adult Tobacco Survey (GATS) is a nationally 
representative household survey that was launched in February 2007 as a new 
component of the ongoing Global Tobacco Surveillance System (GTSS). 
According to that survey, current tobacco smokers in India are 14.9% in which 
cigarette smokers are 5.7%. The overall male prevalence is 24.3% out of 
which current cigarette smokers are 10.3%. 
 Adults who are exposed to second hand smoke at home are 52.3% and 
adults exposed to second hand smoke at work place are 29.9% and adults 
exposed to second hand smoke at public place are 29.0%.
1 
 In India, tobacco consumption is responsible for half the number of all 
the cancers in men and a quarter of all cancers in women, in addition to being 
a risk factor for cardiovascular diseases and chronic obstructive pulmonary 
diseases.
2
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 The World Health Organization predicts that tobacco deaths in India 
may exceed 1.5 million annually by 2020.
3
 There are at least 55 carcinogens in 
cigarette smoke, and presently available data focus on 20 substances that are 
probably involved in lung cancer induction.
4
  
 Nicotine is named after the tobacco plant Nicotian Tabacum, which in 
turn is named after Jean Nicot de Villemain, French Ambassador in Portugal, 
who sent tobacco and seeds from Brazil to Paris in 1560 and promoted their 
medicinal use. Nicotine was first isolated from the tobacco plant in 1828 by 
physician Wilhelm Heinrich Posselt and chemist Karl Ludwig Reimann 
of Germany, who considered it a poison.
5 
 Cotinine is a useful and popular biomarker of tobacco use. Most 
nicotine entering the body (70%–80%) is metabolized into cotinine. Cotinine 
is present in the blood serum, saliva, urine, amniotic fluid, cervical mucus and 
hair of both smokers and non-smokers exposed to tobacco smoke. It has been 
cited as the most useful marker for distinguishing tobacco users from non-
users, for estimating the nicotine intake of tobacco users and for specifying the 
exposure of nonsmokers to second hand smoke.
6 
 
Cotinine has an extended biological half-life of 15 to 40 hours. Its level 
in the body is directly related to the quantity of nicotine absorbed during the 
last few days.
7 
The presence of cotinine indicates exposure to nicotine, either 
from environmental exposure or direct consumption.  
 Introduction 
 
 
3 
 
 
 High-performance liquid chromatography (sometimes referred to as 
high-pressure liquid chromatography), HPLC, is a chromatographic technique 
used to separate a mixture of compounds in analytical chemistry and 
biochemistry with the purpose of identifying, quantifying and purifying the 
individual components of the mixture. HPLC is also considered an 
instrumentation technique of analytical chemistry, instead of a gravimetric 
technique. HPLC has many uses including medical (e.g. detecting vitamin                
D concentrations in blood serum), legal (e.g. detecting performance 
enhancement drugs in urine), research (e.g. purifying substances from a 
complex biological sample, or separating similar synthetic chemicals from 
each other) and manufacturing (e.g. pharmaceutical quality assurance).
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AIM OF THE STUDY: 
 To estimate and compare cotinine level in smokers and non-smokers in 
serum and saliva. 
 
OBJECTIVE OF THE STUDY: 
 To estimate serum cotinine level in non-smokers. 
 To estimate saliva cotinine level in non-smokers. 
 To estimate serum cotinine level in smokers. 
 To estimate saliva cotinine level in smokers. 
 To compare serum and saliva cotinine level in non-smokers and 
smokers. 
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SMOKING 
HISTORY 
 The history of smoking starts among the Native Americans who used it 
for ceremonial purposes 5000 years BC. Christopher Columbus first brought 
tobacco to Europe from the West Indies in 1492. From the beginning it was 
used for medical purposes and in history it is mentioned when the Queen of 
France, Catherine of Medici, was cured from stomach pains by tobacco. She 
got the tobacco from Jean Nicot and named it “Nicotiana”. Soldiers during the 
great European wars spread the use of tobacco, mostly used as snuff or 
smoked in pipes. It was not until the Crimean War, in the middle of 19
th
 
century, that cigarettes became more common. When the first cigarette 
machine was constructed in 1870, cigarette smoking flourished. This was also 
the start for the big tobacco company.
9 
 Cigarette smoke is a complex mixture of chemicals.  Some smoke 
components, such as carbon monoxide (CO), hydrogen cyanide (HCN) and 
nitrogen oxides, are gases.  Others, such as formaldehyde, acrolein, benzene, 
and certain N-nitrosamines, are volatile chemicals contained in the liquid- 
vapor portion of the smoke aerosol.  Still others, such as nicotine, phenol, 
polyaromatic hydrocarbons (PAHs) and certain tobacco-specific nitrosamines 
(TSNAs), are contained in the submicron sized solid particles that are 
suspended in cigarette smoke.  
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 In view of this chemical complexity, cigarette smoke has multiple, 
highly diverse effects on human health.  It is not unexpected that multiple 
chemicals in cigarette smoke can contribute to any single adverse health 
effect.
10 
EPIDEMIOLOGY
11 
 Though smoking prevalence in the western world is decreasing, 
smoking has kept an aura of tough and smart glamour, and around 10,000 new 
young smokers are recruited daily. In total, about 1/3 of the adult population 
smokers and WHO has calculated that 1000 cigarettes are manufactured per 
year per person, including women and children. An early two-fold difference in 
smoking rates is seen in men across different WHO regions, with the lowest 
level in the Eastern Mediterranean Region (34.2%) and the highest in the 
Western Pacific Region (62.3%). Based on these weighted prevalence 
estimates, there are over 1.2 billion smokers across the six WHO regions, 
women being in the minority in the developing countries. 
 Tobacco use prevalence can be decreased by a variety of tobacco 
prevention and control efforts. Reporting on the adverse health effects from 
smoking the anti-smoking debate was accelerated in the 1980's when it was 
shown that passive smoking was also a health hazard. During the 1990's 
numerous conventions, national as well as international, addressed the 
smoking issue. Educational, clinical, regulatory, economic and comprehensive 
approaches are widely used and studied. WHO and European Union, have 
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made up rules and recommendations for how the "pandemic of smoking" can 
be defeated. Tobacco control is highly cost effective. Many countries have 
passed laws on smoke free areas, rules for cigarette commerce and public 
health interventions to control tobacco use.
12 
 As an example in Finland, the Tobacco Control Act was passed as 
early as in 1976. It prohibited smoking in most public places, restricted 
tobacco advertising, and set a 16-year age limit for tobacco purchases. Further 
amendments to the Act were made in 1995, when, for example, the age limit 
for tobacco purchases was raised to 18 years, and in 2000, when ETS was 
included in the national list of carcinogenic substances. Among Finnish adult 
males, smoking prevalence is nowadays one of the lowest in Europe. In 
general, the smoking trends suggest that the impact of tobacco policy is 
decreasing smoking initiation in youth, for example the legislation appears to 
have decreased purchases from commercial sources to minors.
13 
FORMS OF TOBACCO  
 There is a variety of smoking tobacco products on the world market. 
1. Cigarette is any roll of tobacco wrapped in paper or other non-tobacco 
material wrapped in paper with filter-tipped or untipped approximately 
8 mm in diameter, 70–120 mm in length. 
2. Cigar is any roll of tobacco wrapped in leaf tobacco or in any other 
substance containing tobacco. There are four main types of cigars.  
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a. Little cigars contain air-cured and fermented tobacco and are 
wrapped either in reconstituted tobacco or in a cigarette paper 
that contains tobacco and/or tobacco extract. 
b. Small cigars or Cigarillos are small, narrow cigars with no 
cigarette paper or acetate filter. 
c. Regular cigars are up to 17 mm in diameter, 110-150 mm in 
length. 
d. Premium cigars (hand-made from natural, long filter tobacco)  
vary in size, ranging from 12 to 23 mm in diameter and 127 to 
214 mm in length.
14 
 Cigarettes and cigars use blended tobaccos and the type of tobacco 
used in these products has a decisive influence on the physicochemical nature 
of the smoke they produce. 
3. Bidis are the most popular form of smoking of tobacco in India. They 
are also becoming increasingly popular among teenagers in the USA. 
A bidi is made by rolling a rectangular piece of a dried temburni leaf 
around approximately 0.2–0.3g of sun-dried, oriental tobacco and 
securing the roll with a thread. This type of smoking is perceived by 
some as better tasting, cheaper, safer or more natural alternative to 
conventional cigarettes.
15 
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4. Chuttas are coarsely prepared cheroots with 2–9 cm long, prepared by 
rolling local tobacco inside a sun-dried tobacco leaf. They are usually 
the products of cottage or small-scale industries. Nearly 9% of the 
tobacco produced in India is used for making chuttas. It is estimated 
that about 3000 million chuttas are made annually in India. The term 
“reverse smoking” is used to describe smoking while keeping the 
glowing end of tobacco product inside the mouth. Reverse chutta  
smoking is practised extensively by women in the rural areas of 
Visakhapatnam and the Srikakulam district of Andhra Pradesh.
16 
5. Cheroot is a roll made from tobacco leaves. Cheroots were commonly 
smoked by both Indian men and women in South India.  
6. Dhumti is a kind of conical cigar made by rolling tobacco leaf in the 
leaf of another plant. Unlike bidis and chuttas, dhumtis are not 
available from vendors but are prepared by the smokers themselves.
17 
7. Kreteks are types of small cigarettes that contain tobacco 
(approximately 60%), ground clove buds (40%) and cocoa, which 
gives a characteristic flavour and “honey” taste to the smoke. Kreteks 
are indigenous to Indonesia, but are also available in the USA.
14 
8. Pipe smoking is one of the oldest form of tobacco use. The different 
kinds of pipes used for smoking range from the small – stemmed 
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European types made of wood to long-stemmed pipes made from metal 
or other material. 
9. Hookah is an Indian white pipe in which the tobacco smoke passes 
through water before inhalation. It used to be more common among 
women, the reason being that it was inconvenient for men to carry a 
hookah, whereas women remain at home for most of the time. 
10. Hooklis are clay pipes commonly used in Western India. Once the pipe 
is lit, it is smoked intermittently. On average, 15 g of tobacco is 
smoked daily. Hookli smoking was common among men in the 
Bhavnagar district of Gujarat.
18 
11. Chillum is a straight conical pipe made of clay, 10–14 centimeters 
long, held vertically. It is exclusive and common among men and is 
confined to the northern states of India, predominantly rural areas.
19 
BIOCHEMICAL METHODS  
 The term biomarker means a measurement that reflects an interaction 
between a biological system and a chemical, physical, or biological 
environmental agent. Biological quantification of tobacco use is based on 
some aspect of the composition of inhaled tobacco smoke. Tobacco smoke is 
composed of gaseous and particle components. The gaseous component is 
made up of room air, carbon monoxide, nicotine and volatilized hydrocarbons 
such as hydrogen cyanide. The primary particle component of tobacco smoke 
is tar, which carries nicotine. Substances such as nicotine, cotinine, 
thiocyanate, carbon monoxide and some minor alkaloids of nicotine have been 
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identified and tested as biomarkers of both active cigarette smoking and 
second hand smoke exposure (SHS).
20 
NICOTINE 
 The major and most pharmacologically active alkaloid of tobacco is 
nicotine. The amount of nicotine uptake is dependent on a smoker’s inhalation 
behaviours (e.g deep or long inhalation of smoke) and metabolism of nicotine. 
Most nicotine is metabolized into cotinine and eventually excreted (see 
cotinine below). Nicotine may be extracted and measured from blood, saliva, 
and urine.
21 
 More recently. It has been measured from samples of hair and toenails. 
Nicotine as a biomarker agent, however, is of limited use. Any assay using 
nicotine must be very sensitive because of the small amount of nicotine 
present in body fluids. Furthermore, because of its short half-life (2 hrs) and 
individual variation in its rate of metabolism, nicotine levels can be only 
approximated, and may give a biased estimate of tobacco use/exposure.  
THIOCYANATE  
 Tobacco smoke contains high concentrations of hydrogen cyanide gas, 
which is primarily metabolized into thiocyanate (SCN). Like cotinine, SCN 
can be measured in blood, urine and saliva. The following issues affect the 
usefulness of SCN as a biomarker. Though SCN has longer half-life            
(10-14 days), the sensitivity and specificity of the assay method are low. SCN 
levels are influenced by industrial exposure and dietary intake of substances 
like almonds, bamboo shoots, sugar cane, cauliflower, broccoli and beer. 
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Because of these limitations, determination of SCN has not gained wider 
use.
22 
CARBON MONOXIDE  
 Cigarette smoke contains a high concentration of CO in gaseous form. 
Regular cigarette smoking may produce carboxyhemoglobin (COHb) levels 
ranging from 5% (1 pack per day) to 9% (2-3 packs per day), whereas heavy 
cigar smoking can produce COHb levels up to 20%. CO has a half-life of          
4-5 hrs in adults and can be measured in both exhaled alveolar air and blood as 
stated by Stewart 1975. Although CO can be measured by analysis of 
hemoglobin for COHb using a carbon monoxideoximeter instrument, this 
approach is not favoured because the procedure to collect the specimen 
(blood) is invasive. Instead, a much simpler and direct measurement of CO 
can be accomplished using exhaled air and a simple handheld breath analyzer. 
This method does not require the samples, such as those of blood, saliva, or 
urine, to be collected and stored, and only minimal training is needed in using 
the device. The immediately available measurement of CO level, which is 
shared with the smoker, can depict the detrimental effects of smoking. This 
may affect the smoker's subsequent smoking behavior.
23
 
Thus, CO measurement has been used as part of anti-smoking 
campaigns. Researchers have demonstrated high correlations among CO, self-
reported smoking and urinary cotinine as said by Secker-Walker et al. in 1997. 
Exhaled CO has been successfully used to corroborate self-report data, with 
concordance approaching 100%.  
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 Environmental sources of CO can result in CO levels indistinguishable 
from those produced by direct cigarette use, thereby confounding the 
measurement another disadvantage of CO measurement is the relatively short 
half-life of CO (4-5 hrs). In general population, false-negative rates of CO 
measurements have been found to range from 2% to 16%. In addition, the 
sensitivity decreases with infrequent and irregular smoking patterns, causing 
those who are light or atypical smokers to appear indistinguishable from non-
smokers.
24 
A REVIEW OF SALIVA AS DIAGNOSTIC FLUID
25 
 Saliva, the most available and non-invasive bio-fluid of the human 
body, permanently “bathes” the oral cavity and is trying to cope with an ever-
changing milieu.  The oral cavity, a very complex and unique milieu due to its 
dual function, is the only place in the body where the mineralized tissue is 
exposed to the external environment in which there are complex interactions 
between various surfaces such as host soft and hard tissues, food, air and 
microorganisms. Saliva includes a large number of inorganic and organic 
compounds, which act as a "mirror of the body's health”. In addition to its 
other functions, saliva could constitute the first line of defense against 
oxidative stress. Due to its composition and functions, saliva could have a 
significant role in controlling and/or modulating oxidative damages in the oral 
cavity. As a diagnostic fluid, saliva offers distinctive advantages over serum. 
Furthermore, saliva may provide a cost-effective approach for the screening of 
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large populations. Gland-specific saliva can be used for diagnosis of pathology 
specific to one of the major salivary glands. Whole saliva, however, is most 
frequently used for diagnosis of systemic diseases.   
 As we enter the era of genomic medicine, sialochemistry will play an 
increasingly important role in the early detection, the monitoring and 
progression of the systemic and oral diseases. We reviewed the current data 
within literature and of our research concerning clinical potential of the 
saliva.
25 
 Saliva is derived from several types of salivary glands. Each type of 
salivary gland secretes saliva with characteristic composition and properties.  
The secretions from these different glands have been shown to differ 
considerably, to be complex in composition and to be affected by different 
forms of stimulation, time of day, diet, age, gender, a variety of disease states, 
and several pharmacological agents. Whole saliva is a mixed fluid that is 
derived predominantly from 3 pairs of major salivary glands: the parotid, the 
submandibular and the sublingual glands. Approximately 90% of total salivary 
volume results from the activity of these 3 pairs of glands, with the bulk of the 
remainder from minor salivary glands located at various oral mucosal sites. 
The whole saliva also contains gingival crevicular fluid (GCF), mucosal 
transudations, expectorated bronchial and nasal secretions, serum and blood 
derivatives from oral wounds, bacteria, and bacterial products, viruses and 
fungi, desquamated epithelial cells, other cellular components and food debris.  
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Serum constituents that are not part of the normal salivary constituents            
(i.e., drugs and hormones) can reach saliva by several ways: intracellular 
(through passive transfer, by diffusion) and extracellular (ultrafiltration). 
 Serum constituents are also found in whole saliva as a result of GCF 
outflow. Depending on the degree of the inflammation in the gingiva, GCF is 
either a serum transudation or more commonly, an inflammatory exudation 
that contains serum constituents. Saliva can be collected with or without 
stimulation. The best two ways to collect whole saliva are the draining 
method, in which saliva is allowed to drip off the lower lip, and the spitting 
method, in which the subject expectorates saliva into a test tube.   
 Tobacco usage or exposure (via “passive” or “second-hand” smoke) is 
now routinely measured by quantization of levels of salivary nicotine that are 
similar clearance and half-life values as plasma. Monitoring levels of salivary 
nicotine has proven useful in monitoring self-reported compliance with 
smoking cessation programs. Salivary nicotine levels were found to be 
indicative of active and passive smoking. Salivary thiocyanate was also found 
to be an indicator of cigarette smoking; however, nicotine levels are 
considered the most reliable marker .An adequate intake may help smokers to 
avoid cigarette smoke induced oxidative damage and to prevent degenerative 
disease. The smoking causes the decrease in salivary important antioxidants 
levels and the loss of activity of salivary enzymes with antioxidant actions  
can be considered as one of the mechanisms by which the toxic effects of CS 
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initiate oral inflammatory diseases, promote precancerous transformations  
and destroy the oral cavity homeostasis. 
 Evaluation of the quantity of whole saliva is simple and may provide 
information, which has systemic relevance. Quantitative alterations in saliva 
may be a result of medications (at least 400 drugs may induce xerostomia). 
Diuretics, antihypertensives, antipsychotics, antihistamines, antidepressants, 
anticholinergics, antineoplastics, amphetamines, barbiturates, hallucinogens, 
cannabis, and alcohol have been associated with a reduction in salivary flow 
and may lead to oral problems like progressive dental caries, fungal infection, 
oral pain, and dysphagia. Qualitative changes in salivary composition can also 
provide diagnostic information concerning oral problems: increased  levels of 
albumin in whole saliva were detected in patients who received chemotherapy 
as treatment for cancer and subsequently developed stomatitis, reduced 
salivary EGF levels may be important for the progression of radiation-induced 
mucositis, higher levels of salivary nitrate and nitrite, and increased activity of 
nitrate reductase, were found in oral cancer patients compared with healthy 
individuals, and were associated with an increased odds ratio for the risk of 
oral cancer.
25 
 Detection, measurement, and monitoring of drugs many analyses, 
including drugs of abuse, can be measured in saliva and oral fluids. 
Particularly useful where a “yes/no” answer is required, oral fluid based tests 
find wide usage in detection of recreational drugs, including alcohol, 
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amphetamines, barbiturates, benzodiazepines, cocaine, a variety of inhalants, 
lysergic acid diethylamide (LSD), marijuana, opioids, phencyclidine (PCP), 
and tobacco.  The use of saliva for drug monitoring, and the detection of illicit 
drugs, has grown remarkably. Currently, saliva can be used to detect and/or 
monitor nicotine, cannabinoids, cocaine, phencyclidine, opioids, barbiturates, 
diazepams, amphetamines and ethanol, most recently, law enforcement 
agencies have employed saliva-based tests for roadside evaluation of alcohol 
levels and in hospital emergency departments as a rapid means of determining 
whether impaired consciousness is related to alcohol intoxication.
25 
COTININE 
 Cotinine is the major degradation product of nicotine metabolism and 
has a serum half-life of about 17 hours compared to two hours for the parent 
compound. Measurement of cotinine levels can provide a sensitive estimate of 
tobacco smoke exposure. For the purpose of developing epidemiologic 
studies, comparative data on the relative sensitivities of cotinine measurements 
in serum, saliva, and urine are required, but few such data are available. In the 
present study, we compared cotinine levels in samples of serum, saliva and 
urine in nonsmokers, passive smokers, and active smokers.
26 
 Cotinine is a useful and popular biomarker of tobacco use. Most 
nicotine entering the body (70%–80%) is metabolized into cotinine. Cotinine 
is present in the blood serum, saliva, urine, amniotic fluid, cervical mucus and 
hair of both smokers and non-smokers exposed to tobacco smoke. It has been 
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cited as the most useful marker for distinguishing tobacco users from non-
users, for estimating the nicotine intake of tobacco users and for specifying the 
exposure of nonsmokers to second hand smoke.
6
  
 Cotinine has an extended biological half-life (15–40 hrs). Its level in 
the body is directly related to the quantity of nicotine absorbed during the last 
few days.
7 
The presence of cotinine indicates exposure to nicotine, either from 
environmental exposure or direct consumption.  
 An advantage of cotinine as a biomarker is its high sensitivity. It can 
distinguish very low levels, such as from SHS in non-smokers, from levels 
associated with cigarette smoking. Small amounts of cotinine in the body can 
result from ingestion of foods rich in nicotine (such as cauliflower, eggplant, 
potatoes, tomatoes and black tea), but these levels are considered 
insignificant.
27
 Measurement techniques have been developed. Cotinine can be 
quantified in blood, serum, saliva and urine. Various techniques are used for 
quantitative analysis including: (a)  radio immunoassay, (b) high-performance 
liquid chromatography, (c) gas–liquid chromatography and (d) gas 
chromatography combined with mass spectrometry.
28
 Woodward and 
colleagues (1991) compared cotinine levels with those from exhaled CO, self- 
reported tobacco exposure and thiocyanate. The results showed a high 
correlation among all the markers for the smoking group, but a lower 
correlation among the nonsmokers exposed to second hand smoke. The 
investigators concluded that cotinine is the most accurate discriminator 
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between smokers and non-smokers as stated by Woodward et al (1991). In 
other studies, serum cotinine was demonstrated to be a better measure of 
cigarette smoking than was questionnaire.
29 
Exhaled carbon monoxide and 
cotinine (detected in blood, urine or saliva) are sufficiently sensitive, specific 
and feasible for general use, and are therefore frequently used as biomarkers 
of cigarette smoking. 
METHODS TO ESTIMATE COTININE LEVELS 
 High-performance liquid chromatography sometimes referred to as 
high-pressure liquid chromatography HPLC, is a chromatographic technique 
used to separate a mixture of compounds in analytical chemistry and 
biochemistry with the purpose of identifying, quantifying and purifying the 
individual components of the mixture. HPLC is also considered an 
instrumentation technique of analytical chemistry, instead of a gravimetric 
technique. HPLC has many uses including medical (e.g. detecting vitamin D 
concentrations in blood serum), legal (e.g. detecting performance 
enhancement drugs in urine), research (e.g. purifying substances from a 
complex biological sample, or separating similar synthetic chemicals from 
each other) and manufacturing (e.g. pharmaceutical quality assurance). 
 HPLC relies on the pressure of mechanical pumps on a liquid solvent 
to load a sample mixture onto a separation column, in which the separation 
occurs. A HPLC separation column is filled with solid particles (e.g. silica, 
polymers, or sorbents) and the sample mixture is separated into compounds as 
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it interacts with the column particles. HPLC separation is influenced by the 
liquid solvent’s condition (e.g. pressure, temperature), chemical interactions 
between the sample mixture and the liquid solvent (e.g. hydrophobicity, 
protonation and chemical interactions between the sample mixture and the 
solid particles packed inside of the separation column (e.g. Ligand affinity, ion 
exchange. 
 HPLC is distinguished from ordinary liquid chromatography because 
the pressure of HPLC is relatively high, while ordinary liquid chromatography 
typically relies on the force of gravity to provide pressure. Due to the higher 
pressure separation conditions of HPLC, HPLC columns have relatively small 
internal diameter (e.g. 4.6 mm), are short (e.g. 25 mm) and packed more 
densely with smaller particles, which helps to achieve finer separations of a 
sample mixture than ordinary liquid chromatography can. This gives HPLC 
superior resolving power when separating mixtures, and hence it is a popular 
chromatographic technique. 
 The schematic of an HPLC instrument typically includes a sampler by 
which the sample mixture is injected into the HPLC, one or more mechanical 
pumps for pushing liquid through a tubing system, a separation column, a 
digital analyte detector (e.g. a UV/Vis, or a photodiode array (PDA) for 
qualitative or quantitative analysis of the separation, and a digital 
microprocessor for controlling the HPLC components (and user software). 
Many different types of columns are available, varying in size and in the type 
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(i.e. chemistry) of solid packed particle types available. Some models of 
mechanical pumps in a HPLC instrument can also mix multiple liquids 
together, and the recipe or gradient of those liquids can modify the chemical 
interactions that occur in HPLC’s column, and thereby modify the chemical 
separation of the mixture.
8
 
 Gas chromatography (GC), is a common type of chromatography used 
in analytical chemistry for separating and analyzing compounds that can be 
vaporized without decomposition. Typical uses of GC include testing the 
purity of a particular substance or separating the different components of a 
mixture (the relative amounts of such components can also be determined). In 
some situations, GC may help in identifying a compound. In preparative 
chromatography, GC can be used to prepare pure compounds from a mixture. 
 In gas chromatography, the mobile phase (or "moving phase") is a 
carrier gas, usually an inert gas such as helium or an unreactive gas such as 
nitrogen. The stationary phase is a microscopic layer of liquid or polymer on 
an inert solid support, inside a piece of glass or metal tubing called a column 
(an homage to the fractionating column used in distillation). The instrument 
used to perform gas chromatography is called a gas chromatograph                     
(or "aerograph", "gas separator"). 
 The gaseous compounds being analyzed interact with the walls of the 
column, which is coated with different stationary phases. This causes each 
compound to elute at a different time, known as the retention time of the 
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compound. The comparison of retention times is what gives GC its analytical 
usefulness. 
 Gas chromatography is in principle similar to column chromatography 
(as well as other forms of chromatography, such as HPLC, TLC), but has 
several notable differences. Firstly, the process of separating the compounds in 
a mixture is carried out between a liquid stationary phase and a gas mobile 
phase, whereas in column chromatography the stationary phase is a solid and 
the mobile phase is a liquid. (Hence the full name of the procedure is "Gas–
liquid chromatography", referring to the mobile and stationary phases, 
respectively). Secondly, the column through which the gas phase passes is 
located in an oven where the temperature of the gas can be controlled, whereas 
column chromatography (typically) has no such temperature control. Thirdly, 
the concentration of a compound in the gas phase is solely a function of the 
vapor pressure of the gas. 
 Gas chromatography is also similar to fractional distillation, since both 
processes separate the components of a mixture primarily based on boiling 
point (or vapor pressure) differences. However, fractional distillation is 
typically used to separate components of a mixture on a large scale, whereas 
GC can be used on a much smaller scale (i.e. microscale). 
 Gas chromatography is also sometimes known as vapor-phase 
chromatography (VPC), or gas–liquid partition chromatography (GLPC). 
These alternative names, as well as their respective abbreviations, are 
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frequently used in scientific literature. Strictly speaking, GLPC is the most 
correct terminology, and is thus preferred by many authors.
30
 
 Gas chromatography–mass spectrometry (GC-MS) is a method that 
combines the features of gas-liquid chromatography and mass spectrometry to 
identify different substances within a test sample. Applications of GC-MS 
include drug detection, fire investigation, environmental analysis, explosives 
investigation, and identification of unknown samples. GC-MS can also be 
used in airport security to detect substances in luggage or on human beings. 
Additionally, it can identify trace elements in materials that were previously 
thought to have disintegrated beyond identification. 
 GC-MS has been widely heralded as a "gold standard" for forensic 
substance identification because it is used to perform a specific test. A specific 
test positively identifies the actual presence of a particular substance in a given 
sample. A non-specific test merely indicates that a substance falls into a 
category of substances. Although a non-specific test could statistically suggest 
the identity of the substance that could lead to false positive identification.
31
 
 Radioimmunoassay (RIA) is a very sensitive in vitro assay technique 
used to measure concentrations of antigens (for example, hormone levels in 
the blood) by use of antibodies. As such, it can be seen as the inverse of a 
radio binding assay, which quantifies an antibody by use of corresponding 
antigens. 
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 Although the RIA technique is extremely sensitive and extremely 
specific, requiring specialized equipment, it remains the least expensive 
method to perform such tests. It requires special precautions and licensing, 
since radioactive substances are used. Today it has been supplemented by the 
ELISA method, where the antigen-antibody reaction is measured using 
calorimetric signals instead of a radioactive signal. However, because of its 
robustness, consistent results and low price per test, RIA methods are again 
becoming popular. It is generally simpler to perform than a bioassay. 
 The RAST test (radioallergosorbent test) is an example of 
radioimmunoassay. It is used to detect the causative allergen for an allergy.
32
 
 Haley et al (1983)
33
 conducted a study in which, Biochemical 
determinations of plasma and salivary cotinine and thiocyanate were used to 
differentiate smokers from non-smokers and to follow daily smoking patterns 
in smokers. Results indicate that cotinine is better suited than thiocyanate to 
determine smoking status in large scale epidemiologic studies and to follow 
alterations in smoking behavior over periods of time. Salivary cotinine is a 
reliable alternative to plasma for validation of smoking status and for 
following changes in daily smoking patterns.  
 Jarvis et al (1984)
34
 conducted a study in which, One hundred non-
smoking patients attending hospital outpatient clinics reported their degree of 
passive exposure to tobacco smoke over the preceding three days and provided 
samples of blood, expired air, saliva and urine. Although the absolute levels 
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were low, the concentration of cotinine in all body compartments surveyed 
was systematically related to self-reported exposure. Salivary nicotine 
concentration also showed a linear increase with degree of reported exposure, 
although this measure was sensitive only to exposure on the day of testing. 
Measures of carbon monoxide, thiocyanate and plasma nicotine concentrations 
were unrelated to exposure. The data indicate that cotinine provides a valid 
marker of the dose received from passive smoke exposure. The non-invasive 
samples of urine and saliva are particularly suited to epidemiological 
investigations. Detailed questionnaire items may also give valuable 
information. 
 Machacek and Jiang et al (1986)
35 
carried out a study in which, 
measurement of cotinine, a nicotine metabolite, has been studied as a method 
for monitoring smoking behavior and determining smoking status. We 
describe a specific, sensitive method for quantifying it in plasma and saliva by 
reversed-phase paired-ion liquid chromatography and detection by absorbance 
at 257 mm. The cotinine is extracted with methylene chloride and                         
2-phenylimidazole is the internal standard. Cotinine peak heights are linearly 
related to the amount on the column from 0 to 500 ng. The mean (± SD) 
concentration of cotinine in plasma of 31 passively exposed nonsmokers was 
2.1±1.6p.g/L (range, 0-7.9 g/L). The regression of saliva cotinine 
concentration (y) on plasma cotinine concentration (x) at 0, 24, and 48 h in 10 
smokers who refrained from smoking for 48 h was y (p.g/L) = 1.155x (g/L) + 
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0.245 (r =0.986). The efficacy of cotinine as a biological marker was 
determined at 0, 24, and 48 h of smoking abstinence. 
 
 Jarvis et al (1987)
24 
conducted a study in which questionnaire and 
biochemical measures of smoking were studied in 211 hospital outpatients. 
Eleven different tests of smoke intake were compared for their ability to 
categorize smokers and nonsmokers correctly. The concentration of cotinine, 
whether measured in plasma, saliva, or urine, was the best indicator of 
smoking with sensitivity of 96-97 percent and specificity of 99-100 percent. 
Thiocyanate provided the poorest discrimination. Carbon monoxide measured 
as blood carboxyhaemoglobin or in expired air gave sensitivity and specificity 
of about 90 percent. Sensitivities of the tests were little affected by the 
presence among the claimed nonsmokers of a group of 21 "deceivers" who 
concealed their smoking. It is concluded that cotinine is the measure of choice, 
but for most clinical applications carbon monoxide provides an acceptable 
degree of discrimination and is considerably cheaper and simpler to apply.
 
 Abrams et al (1987)
36
 performed a study to determine the accuracy 
and reliability of saliva cotinine as an objective measure of smoking status was 
examined in two field studies. Saliva was collected from smokers and 
nonsmokers with repeated samples taken from a randomly selected subset of 
the smokers. Results indicated perfect classification of smokers versus 
nonsmokers and acceptable reliability of repeated samples. Using a cut-off of 
10 ng/ml as suggested by Benowitz, perfect discrimination of smokers from 
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nonsmokers was achieved. All smokers had salivary cotinine levels greater 
than 10 ng/ml (mean = 349.2, SD = 195.4, range = 26-933) and all of the 
nonsmokers had levels of less than 10 ng/ml (mean = 0.3, SD = 1.6,              
range = 0-9).
 
 Coutlas et al (1987)
37 
conducted a population-based household survey 
of respiratory disease in 2,029 children and adults and measured salivary 
cotinine levels by radioimmunoassay in 1,360 nonsmokers and ex-smokers. At 
all ages median and mean cotinine levels among nonsmoker and ex-smokers 
increased with the number of smokers in the home. The prevalence of a 
detectable level of cotinine was about 35% for those not living with a cigarette 
smoker and was greater with the number of cigarettes smoked by household 
members. In a multiple logistic regression model, the major determinants of a 
detectable level of cotinine in children where mother's smoking (odds ratio 
(OR) » 3.2), father's smoking (OR = 2.1) and smoking of other household 
members (OR ~ 4.0). Among adults, the effects of spouse's smoking were 
smaller with OR = 1.3 and 1.4 for husband's and wife's smoking, respectively. 
They concluded that in the general population cotinine can be frequently 
detected in the saliva of nonsmokers, even among those not living with a 
smoker.
 
 Langone et al (1988)
38
 carried out  a study to determine the value of a 
monoclonal antibody-based ELISA for measuring cotinine in saliva and urine 
of active and passive smokers was assessed. Cotinine (mean +/- SEM) was 
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detected in all 26 saliva (392 +/- 74 ng/ml) and 27 urine (4264 +/- 508 ng/ml 
creatinine; 2566 +/- 364 ng/ml) samples from smoking parents, but in only 
two of 36 saliva and one of 37 urines from nonsmokers (P less than 0.001). 
Similarly, mean cotinine levels in 30 saliva samples (4.67 +/- 1.10 ng/ml) and 
33 urine samples (35.5 +/- 8.8 ng/mg creatinine; 25.3 +/- 8.1 ng/ml) from 
passively exposed children were significantly higher (P less than 0.001) than 
in fluids of 36 unexposed children. In adult smokers there was a positive 
correlation between salivary and urinary cotinine (P=0.002) and a close 
relationship between urinary cotinine and cigarettes smoked per day               
(P = 0.066). The ELISA gives a reliable quantitative measure of cotinine as an 
indicator of active and passive exposure to tobacco smoke. However, 
correlations with cotinine can be overestimated if large numbers of 
nonsmokers are included in the comparison.
 
 Michael A wall et al (1988)
39
 studied 98 subjects in age range of             
24-66 years by gas liquid chromatography where the samples were categorized 
into  non- smokers, passive and active smokers and found that only a minority 
of nonsmokers and detectable levels of cotinine in their serum (n=1) or saliva 
(n=1). The study concluded that active smokers of < 10 cigarettes per day had 
lower mean cotinine levels in both serum and saliva when compared to 
subjects who smoked >10 cigarettes. 
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 Lee et al (1993)
40
 conducted a study in which the current  and passive 
smoking are associated with risk factors and the potential for confounding 
arising from these associations was  studied using a representative sample of 
9003 British adults. The distribution of 33 lifestyle factors generally 
considered associated with adverse health were compared in current smokers, 
ex-smokers, never smokers living with a smoker ("passive smokers") and  
never smokers not living with smokers of the 33 risk factors 27 showed a 
significantly higher prevalence in heavy smokers than in never smokers and 
only two showed a lower prevalence. For many risk factors, prevalence 
increased with amount smoked, decreased with time of smoking cessation and 
was increased in passive smokers. The possible magnitude of bias from 
confounding by the risk factors is estimated. It is concluded that confounding 
by multiple risk factors may be an important issue in smoking studies where 
weak associations are observed. This applies particularly to studies 
investigating the possible association of passive smoking with various health 
effects.
 
 Istvan et al (1994)
41
 carried out a study which investigates the relation 
of salivary cotinine and of the reported number of cigarettes smoked per day 
to body mass index among middle-aged male (n = 3,538) and female              
(n = 2,096) cigarette smokers participating in screening for entry to a clinical 
trial of early intervention in chronic obstructive pulmonary disease (Lung 
Health Study) from 1986 to 1989. Both before and after controlling for age, 
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education, and alcohol intake, the number of cigarettes smoked per day was 
positively related to body mass index among both men and women, whereas 
salivary cotinine levels were negatively related to body mass index among 
both men and women. The opposite relation of salivary cotinine and of 
reported number of cigarettes smoked per day to body mass index is discussed 
with regard to nicotine metabolism, energy intake, and measurement issues in 
the assessment of cigarette smoke exposure. 
 
 Ettar et al (2000)
42
 collected self-reported data on smoking habits and 
saliva samples that were analyzed for cotinine concentration in 222 smokers 
and 97 nonsmokers. Participants were members of the University of Geneva 
(Switzerland) in 1995. The 207 cigarette-only smokers smoked on average 
10.7 cigarettes/day and had a median concentration of cotinine of 113 ng/ml. 
The cotinine concentration was moderately associated with the number of 
cigarettes smoked per day (+14 ng/ml per additional cigarette, p < 0.001,              
Ff = 0.45) and was 54 ng/ml higher in men than in women after adjustment for 
cigarettes per day and for the Fagerstrom test for Nicotine Dependence. The 
cotinine level was not associated with the nicotine yield of cigarettes (r= 0.08). 
In nonsmokers, the median concentration of cotinine was 2.4 ng/ml. The 
cotinine concentration was 1.5 times higher in nonsmokers whose close 
friends/spouses were smokers than in nonsmokers (p = 0.05). A cutoff of           
7 ng/ml of cotinine distinguished smokers from nonsmokers with a sensitivity 
of 92.3% and a specificity of 89.7%; a cutoff of 13 ng/ml provided equally 
 Review of Literature 
 
 
31 
 
 
satisfactory results (sensitivity, 86.5%; specificity, 95.9%). This study 
provides evidence for the construct validity of both questionnaires and saliva 
cotinine for the assessment of active and passive exposure to tobacco smoke. 
 
 Nikajima et al (2000)
43
 demonstrated, highly sensitive and reliable 
method for the determination of nicotine and its metabolite cotinine in human 
plasma by high-performance liquid chromatography was developed. Nicotine 
and cotinine were extracted from alkalinized plasma with dichloromethane 
and the volatility of nicotine was prevented by the addition of conc. HCl to the 
organic solvent during evaporation. The sensitivity of quantiﬁcation at 260 nm 
absorption was improved by using a noise-base clean Uni-3 to 0.2ng/ml 
nicotine and 1.0 ng/ml cotinine. The method was validated over linear ranges 
of 0.2–25.0 ng/ml for nicotine and 1.0–80.0 ng/ml for cotinine.  
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TOPIC OF STUDY: 
 Estimation and comparison of serum and saliva cotinine level in 
smokers and non- smoker. 
Study design: The Present study is an analytical case control study 
Study duration: This study was conducted between March 2012 to August 
2012 in the Department of Oral Medicine and Radiology of Ragas Dental 
College and Hospital with laboratory support from Sri Ramachandra Medical 
college, Porur, Chennai. 
Study population: 
 A total number of 30 patients (15 smokers and 15 non- smokers) were 
involved in the study. 
Obtaining approval from the authorities: 
 Permission from the Institutional Review Board of Ragas Dental 
College & Hospital, Chennai was obtained before starting the study. 
 Consent letter from the participants of the study was obtained in both 
Tamil and English. 
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MATERIALS 
ARMAMENTARIUM USED 
Examination of the patient 
1. Dental chair with halogen lamp 
2. Plain mouth mirror 
3. Dental probe 
4. Mouth mask 
5. Disposable latex gloves 
Salivary sample collection 
1. Disposable mouth mask 
2. A pair of sterile gloves 
3. Sterile plastic containers for collection of saliva 
4. Refrigerator 
Blood sample collection (for extracting the serum) 
 Disposable 5 ml plastic syringe and 23 gauge needle  
 Vacutainer coated with Ethylene diamine tetra acetic acid (EDTA) 
 Torniquet 
 Sterile Cotton 
 70% alcohol as surface disinfectant 
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 Sterile vials 
 Refrigerator 
 Cotinine estimation 
1. Nicotinine and cotinine 
2. Acetanilide 
3. Sodium hydroxide 
4. Dichloromethane 
5. Conc. Hydrochloric acid 
6. Vaccum evaporator 
7. High performance liquid chromatography 
1. L – 7100 pumo 
2. L – 7400 u – v detector 
3. L – 7500 autosampler 
4. L – 7500 integrator 
5. 865 co- colum oven  
6. Phosphoric acid 
METHODOLOGY 
 The study comprised of a total number of 30 male patients. Out of the 
30 patients, 15 were non smokers and the other 15 were smokers 
 
 Materials and Methods 
 
 
35 
 
 
STUDY GROUP 
 The study group comprised of 15 male patients in the age group of 18 
yrs and above with cigarrete smoking habit visiting the outpatient department 
of Ragas Dental College and Hospital, Chennai. 
INCLUSION CRITERIA 
 Male patients aged 18 yrs and above. 
 Cigarrete smokers only 
EXCLUSION CRITERIA 
 Female patients 
 Patients with Diabetes , hypertension and any known systemic diseases  
 Patients who are currently under medication 
 Other types of tobacco smokers 
CONTROL GROUP 
 The control group comprised of 15 male patients in the age group of            
18 yrs and above with no smoking habit visiting the outpatient department of 
Ragas Dental College and Hospital, Chennai. 
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INCLUSION CRITERIA 
 Male patients aged 18 yrs and above. 
 Non smokers. 
EXCLUSION CRITERIA 
 Female patients. 
 Patients with Diabetes, hypertension and any known systemic diseases.  
 Patients who are currently under medication. 
INFORMED CONSENT 
 Permission from Institutional Review Board of Ragas Dental College 
and Hospital, Uthandi and Innovis Laboratory, Sri Ramachandra Medical 
College and Research institute, Porur, Chennai was obtained before starting 
the study. 
 Informed consent was obtained from all the subjects before including 
them in the study. Consent was prepared in both Tamil and English in letter 
format. 
EXAMINATION OF THE SUBJECTS 
 The patients included in the study were made to sit comfortably on a 
dental chair and interrogated for demographic details and habits. An intraoral 
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examination was carried under halogen light. The findings were recorded in 
the proforma. Serum and saliva were collected. 
SERUM SAMPLE COLLECTION
42
 
1. Blood samples are taken from the vein in the antecubital fossa. The 
tourniquet is set around the upper arm of the subject, search for the 
cubital vein by inspecting and palpating and then sterilize the 
injection site. The vein can be anchored by placing the thumb about 
two centimeters below the vein and pulling gently to make the skin 
a little taut. After that, the needle, beveled upward, should be 
pushed smoothly and quickly into the vein, to minimize the 
possibility of hemolysis as a result of vascular damage. 
Immediately after the insertion, the tourniquet should be released to 
minimize the effect of hemoconcentration. 5 ml of venous blood 
was drawn. EDTA and Sodium Fluoride were added to prevent the 
coagulation of blood. 
2. For the determination of the nicotine concentration, the plasma 
sample (1 ml) was alkalinized by 50 ml of 10 M NaOH. After the 
addition of 10 ng of acetanilide as an internal standard, the mixture 
was extracted with 4 ml of dichloromethane by shaking for 10 min. 
3. After centrifugation at 1000 g for 10min, 25 ml of conc. HCI added 
to the organic fraction for the determination of the nicotine 
concentration. The organic fraction was evaporated with a vacuum 
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evaporator at 408
◦
c. The residue was redissolved in 100 ml of the 
mobile phase and then an 80-ml portion of the sample was 
subjected to HPIC 
4. For the determination of the cotinine concentration, the plasma 
sample (0.5ml) was alkalinized by 25 ml of 10 M NaOH and 
extracted with 4 ml of dichloromethane by shaking for 10 min. the 
organic fraction was evaporated with a vacuum evaporator at 408c 
without the addition of conc. HCI 
The residue was redissolved in 100ml of the mobile phase and then an 
80ml portion of the sample was subjected to HPLC.  
SALIVA SAMPLE COLLECTION 
The subjects were required to abstain from drinking, smoking or using 
oral hygiene products for at least 1 hour before saliva collection.  The patients 
were asked to rinse their mouth with water and were made to sit comfortably 
in a chair. The patients were asked to pool the saliva in the mouth till the 
fullness is felt and then asked to spit in the given sterile plastic container with 
5 ml reading. This was repeatedly done for 5 times to collect 5 ml of saliva. 
The sample is freezed to - 20°c for the procedure to be carried out. All samples 
were centrifuged at 3000 rpm for 10 min to remove particulate materials and 
the clean supernatant was processed immediately for estimation of cotinine 
which was then subjected to HPLC. 
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High – performance liquid chromatography42 
1. Chromatography was performed using an L-7100 pump (Hitachi, 
Tokyo, Japan), an L-7400 UV detector (Hitachi), an L-7200 auto 
sampler (Hitachi), an L-7500integrator (Hitachi), and an 865-CO 
column oven (Jasco, Tokyo, Japan) 
2. The flow-rate was1.0ml/min and the column temperature was 358

C. 
The eluent was monitored at 260nm with a noise-base clean Uni -3 
(Union, Gumma, Japan) 
3. For the determination of the nicotine concentration, the analytical 
column was a Hichrome 5C18 (15034.6 mm, 5mm) column (Tomsic, 
Tokyo, Japan) and the mobile phase was 7% CH OH, 2 mm Nah PO, 
3240.2% phosphoric acid, and 1mM heptane sulfonate sodium. For the 
determination of the cotinine con-centration, the analytical column was 
a capecell Pak C UG 120 (2503.6 mm, 4mm) column (Shiseido, 18 
Tokyo, Japan) and the mobile phase was 2% CH OH, 2 mm Nah PO, 
0.1% phosphoric acid, 324 and 1 mm heptane sulfonate sodium. 
4. Nicotine was quantified by comparison with the standard curves using 
the HPLC peak height ratios to acetanilide. Cotinine was quantified by 
comparing the HPLC peak heights to those of authentic standard. 
 The values were entered in the case sheet proforma and subjected to 
statistical analysis 
STATISTICAL ANALYSIS 
All the data were entered in Microsoft excel sheets. Statistical analysis 
was done using SPSS software.  
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Mean: defined as sum of values (X) divided by the number of values (N) and 
denoted by.                            
P > 0.05 = Difference is not significant 
P ≤ 0.05 = Difference is significant (S) 
P ≤ 0.01 = Difference is highly significant (S) 
P ≤ 0.001 = Difference is very highly significant (HS) 
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Fig.1: Armamentarium for clinical examination 
 
 
 
Fig.2: Serum Collection  
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Fig.3: Ependorff Tubes for saliva collection 
 
     
Fig.4: Blood Sample Collection 
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Fig.5: Blood sample 
 
 
Fig.6: Saliva Sample Collection 
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Fig.7: Sample stored at – 20C 
 
 
 
 
 
 
 
 
 
 
Fig.8: Centrifuge Tubes 
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Fig.9: Lab Procedure Being Carried Out 
 
 
 
Fig.10: Centrifuge Machine 
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Fig.11: High Performance Liquid Chromatography System 
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The present study is a Case control study conducted by Ragas Dental 
College and Hospital and Sri Ramachandra Medical College and Research 
Institute, Porur, Chennai. It was devised to estimate and compare the Serum 
and Saliva cotinine levels in Smokers and Non smokers with High profile 
Liquid Chromatography. The study was conducted between March 2012 and 
August 2012 with15 Smokers and 15 non Smokers. The data obtained from 
the study was statistically analysed. The results extracted were compared with 
various variables included in the study and are presented here. 
Table 1: Age wise distribution of Subjects in Control group 
This table denotes age wise distribution of subjects in Control group. 
The age of 15 subjects in the control group was divided in to less than 30 and 
more than 30 years. Out of the 15 subjects 4 (26.7%) were in the age group of 
less than 30 years and 11 (73.3%) were in the age group of more than 30 
years. 
Table 2: Age wise distribution of Subjects in study group 
This table denotes age wise distribution of subjects in study group. The 
age of 15 subjects in the study group was divided in to less than 30 and more 
than 30 years. Out of the 15 subjects 10 (66.7%) were in the age group of less 
than 30 years and 5 (33.3%) were in the age group of more than 30 years. 
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Table 3: Age wise distribution of Subjects in control and study groups 
This table denotes age wise distribution of subjects in control and 
study group. Among the control group of 15 subjects, the mean age obtained is 
34 years with a standard deviation of 19.13 and among the study group of 15 
subjects the mean age obtained is 44 years with a standard deviation of 15.65. 
The p value obtained is 0.128 which is > 0.05 and is insignificant. 
Table 4: Serum cotinine level in control group  
This table denotes Serum cotinine level in control group. The Serum 
cotinine level in the control group was divided in to levels below 3 ng/dl and 3 
– 5 ng/dl. Among 15 subjects Serum cotinine levels obtained were below 3 
ng/dl in 12 (80%) subjects and between 3 – 5 ng/dl in 3 (20%) of the subjects. 
Table 5: Serum cotinine level in study group 
This table denotes Serum cotinine level in study group. The Serum 
cotinine level in the study group was divided in to levels below 5 - 50 ng/dl 
and above 50 ng/dl. Among 15 subjects Serum cotinine levels obtained were 5 
- 50 ng/dl in 6 (40%) subjects and above 50 ng/dl in 9 (60%) of the subjects. 
Table 6: Serum cotinine level in control and study groups 
This table denotes Serum cotinine level in control and study group. 
Among 15 subjects in 12 (80%) of the control group subjects the Serum 
cotinine levels obtained were below 3 and 3 (20%) of the subjects showed 
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values in the range of 3- 5 ng/dl. In our study group subjects, the serum 
cotinine levels as well as saliva cotinine levels of below 3ng/dl and 3-5 ng/dl 
were found in zero subjects.  Among 15 subjects in 12 (80%) of the study 
group subjects the Serum cotinine levels obtained were 5 – 50 ng/dl in 6 
(40%) subjects  and above 50ng/dl in 9 (60%) of the subjects. And none (0%) 
of the control group subjects showed values above 50 ng/dl and between                
5-50 ng/dl. The p value obtained is 0.000 which is < 0.001 and is highly 
significant. 
Table 7: Saliva cotinine level in control group 
This table denotes saliva cotinine level in control group. The saliva 
cotinine level in the control group was divided in to levels below 3 ng/dl and        
3–5 ng/dl. Among 15 subjects saliva cotinine levels obtained were below               
3 ng/dl in 13 (86.7%) subjects and between 3–5 ng/dl in 2 (13.3%) of the 
subjects. 
Table 8: Saliva cotinine level in study group 
This table denotes saliva cotinine level in study group. The saliva 
cotinine level in the study group was divided in to levels between 5 - 50 ng/dl 
and above 50 ng/dl. Among 15 subjects saliva cotinine levels obtained were         
5-50 ng/dl in 7 (46.7%) subjects and above 50 ng/dl in 8 (53.3%) of the 
subjects. 
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Table 9: Saliva cotinine level in control and study groups 
This table denotes saliva cotinine level in control and study group. 
Among 15 subjects in 13 (86.7%) of the control group subjects the Serum 
saliva levels obtained were below 3 ng/dl and 2 (13.3%) of the subjects 
showed values in the range of 3- 5 ng/dl. And none (0%) of the study group 
subjects showed values below 3 ng/dl and between 3 – 5 ng/dl.  Among 15 
subjects in 7(46.7%) of the study group subjects the saliva cotinine levels 
obtained were 5 – 50 ng/dl and above 50 ng/dl in 8 (53.3%) of the subjects. 
And none (0%) of the control group subjects showed values 5 - 50 ng/dl and 
above 50 ng/dl. The p value obtained is 0.000 which is < 0.05 and is highly 
significant. 
Table 10: Distribution of study group subjects according to number of 
cigarettes smoked per day  
This table denotes the distribution of study group subjects according to 
number of cigarettes smoked per day. The number of cigarettes smoked per 
day was divided in to 1 – 10 and  11 – 30. Among 15 study group subjects 10 
(66.7%) of them consumed 1 – 10 cigarettes per day and 5 (33.3%) of them 
consumed 11 – 30 per day.   
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Table 11: Distribution of study group subjects according to number of 
years of smoking  
This table denotes the distribution of study group subjects according to 
number of years of smoking. The number of years of smoking was divided in 
to below 10 and 11 – 40 years. Among 15 study group subjects 12 (80%) of 
them were smoking for less than 10 years and 3 (20%) of them smoked in the 
range of 11 – 40 years.   
Table 12: Correlation between age in year and Serum cotinine level in 
control group 
This table denotes the correlation between age in year and Serum level 
in control group. Among 15 subjects  all of the 4 (26.7%) subjects who were 
less than 30 years old showed values below 3  and among out of 11 (73.3%) of 
the subjects who were more than 30 years old 8 (72.7%)  of them showed  
below 3 and 3(27.3%) of them showed values between 3-5. The p value 
obtained is 0.243 which is > 0.05 and is insignificant. 
Table 13: Correlation between age in year and saliva cotinine level in 
control group 
This table denotes the correlation between age in year and saliva level 
in control group. Among 15 subjects out of 4 (26.7%) subjects, 3 of them who 
were less than 30 years old showed values below 3 ng/dl and 1 subject showed 
value of  3 – 5 ng/dl. And out of 11 (73.3%) subjects who were more than 30 
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yrs. old, 10 of them showed values below 3 ng/dl and 1 subject between 3 – 5 
ng/dl. The p value obtained is 0.423 which is > 0.05 and is insignificant. 
Table 14: Correlation between Serum and saliva cotinine levels in control 
group 
This table denotes correlation between Serum and saliva cotinine 
levels in control group. The Serum and saliva cotinine levels in control group 
was divided in to below 3 ng/dl and 3-5 ng/dl. Out of the 15 subjects 12 (80%) 
of them among which 11 showed values below 3 ng/dl and 1   showed value in 
the range of  3 – 5 ng/dl. Out of the 3(20%) of the subjects 2 of them showed 
values below 3 ng/dl and 1 showed between 3 – 5 ng/dl. The p value obtained 
is 0.255 which is > 0.05 and is insignificant.  
Table 15: Correlation between Serum and saliva cotinine levels in study 
group 
This table denotes correlation between Serum and saliva cotinine 
levels in study group. The Serum and saliva cotinine levels in study group was 
divided in to 5 – 50 ng/dl and above 50 ng/dl. Out of the 15 subjects 6 (40%) 
subjects  out of which 5 showed values in the range of 5 – 50 ng/dl and 1 
subject showed value above 50 ng/dl and 9 (60%) subjects out of which 2 of 
them showed values of 5 – 50 ng/dl and 7 showed above 50 ng/dl. The p value 
obtained was 0.020 which is < 0.05 and is significant. 
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Table 16: Correlation between age in year and Serum cotinine level in 
study group 
This table denotes the correlation between age in year and Serum level 
in study group. The age group was divided in to less than 30 and more than 30 
and Serum level was divided in to 5 – 50 ng/dl and above 50ng/dl.  Among 15 
subjects 10 (66.7%) of them who were less than 30 years old, out of which 5 
of them showed values of 5 – 50 ng/dl  and 5 of them showed values more 
than 50 ng/dl,  and in 5 (33.3%) of the subjects who were more than 30 years 
old 1 subject showed value of 5-50 ng/dl and 4  showed values more than 50 
ng/dl. The p value obtained is 0.264 which is > 0.05 and is insignificant. 
Table 17: Correlation between age in year and saliva cotinine level in 
study group 
This table denotes the correlation between age in year and saliva level 
in study group. The age group was divided in to less than 30 and more than 30 
and saliva level was divided in to 5 – 50 ng/dl and above 50ng/dl.  Among 15 
subjects 10 (66.7%) of them who are less than 30 years old out of which 7 of 
them showed values 5 – 50 ng/dl and 3 of them showed values more than             
50 ng/dl.  And in 5 (33.3%) of the subjects none of them showed values                
5–50 ng/dl and 5 of them showed values above 50 ng/dl. The p value obtained 
is 0.010 which is < 0.05 and is significant. 
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Table 18: Correlation between number of cigarettes smoked per day and 
serum cotinine level in study group 
This table denotes correlation between number of cigarettes smoked 
per day and plasma level in study group. The number of cigarettes consumed 
was divided in to 1 – 10 and 11 – 30 and plasma level was divided in to 5 – 50 
and above 50ng/dl.  Among 15 subjects 10 (66.7%) of them were smoking in 
the range of 1-10 cigarettes per day out of which 6 of them show values in the 
range of 5 – 50 ng/dl and 4 of them showed value above 50 ng/dl and in those 
subjects who were smoking in the range of 11-30 cigarettes per day, all 5 
(33.3%) of them showed values above 50 ng/dl.  The p value obtained is 0.025 
which is < 0.05 and is significant. 
Table 19: Correlation between number of cigarettes smoked per day and 
saliva cotinine level in study group 
This table denotes correlation between number of cigarettes smoked 
per day and saliva level in study group. The number of cigarettes consumed 
was divided in to 1 – 10 and 11 – 30 and saliva level was divided in to 5 – 
50ng/dl and above 50ng/dl.  Among 15 subjects 10 (66.7%) of them out of 
which 6 of them show values in the range of 5 – 50 ng/dl and 4 of them 
showed value above 50 ng/dl who were in the range of 1- 10 yrs. of smoking 
and in those subjects who were in 11-40 yrs. of smoking 5 (33.3%) of them 
among which 1 showed value of 5 – 50 ng/dl and 4 of them showed value 
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above 50 ng/dl. The p value obtained is 0.143 which is > 0.05 and is 
insignificant. 
 Table 20: Correlation between number of years of smoking and Serum 
cotinine level in study group 
This table correlation between number of years of smoking and Serum 
cotinine level in study group. The number of years of smoking was divided in 
to below 10 and 11 – 40 years and Serum cotinine  level was divided in to              
5 – 50 ng/dl and above 50ng/dl.  Among 15 subjects 12 (80%) of them out of 
which 5 of them showed values in the range of 5 – 50 ng/dl and 7 of them 
showed value above 50 ng/dl who were in the range of  below 10 yrs. of 
smoking and in those subjects who are in 11-40 yrs. of smoking , 3 (20%) of 
them among which 1 showed value of 5 – 50 ng/dl and 2 of them showed 
value above 50 ng/dl.  The p value obtained is 0.792 which is > 0.05 and is 
insignificant. 
Table 21:  Correlation between number of years of smoking and saliva 
cotinine level in study group 
This table correlation between number of years of smoking and saliva 
cotinine level in study group. The number of years of smoking was divided in 
to below 10 and 11 – 40 years and saliva cotinine level was divided in to                
5–50 ng/dl and above 50ng/dl.  Among 15 subjects 12 (80%) of them out of 
which 7 of them showed values in the range of 5–50 ng/dl and 5 of them 
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showed value above 50 ng/dl who were in the range of ds below 10 yrs. of 
smoking and in those subjects who are in 11-40 yrs. of smoking all 3 of them 
showed value above 50 ng/dl and none of them showed values in range of             
5- 50 ng/dl.  The p value obtained is 0.070 which is > 0.05 and is insignificant. 
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Table 1: Age wise distribution of Subjects in Control group 
 
 
 
 
 
 
Table 2: Age wise distribution of Subjects in study group 
Age in years Frequency Percent 
Less than 30 10 66.7 
More than 30 5 33.3 
Total 15 100.0 
 
 
Table 3: Age wise distribution of Subjects in control and study groups 
Age group in 
year 
Number Mean Age Std. 
Deviation 
P Value 
Non  
Smoking 
15 34.07 19.13 
0.128 
Smoking 15 44.07 15.65 
 
 
 
 
Age Frequency Percent 
Less than 30 4 26.7 
More than 30 11 73.3 
Total 15 100.0 
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Table 4: Serum cotinine level in control group 
Serum cotinine  
level in ng/dl Frequency Percent 
Below 3 12 80.0 
3-5 3 20.0 
Total 15 100.0 
 
 
 
 
Table 5: Serum cotinine level in study group 
Serum 
Cotinine level 
in ng/dl Frequency Percent 
5-50 6 40.0 
Above 50 9 60.0 
Total 15 100.0 
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Table 6: Serum cotinine level in control and study groups 
Serum 
cotinine level 
in ng/dl 
 Group Total 
P Value 
 Non-Smokers Smokers  
Below 3 Count 12 0 12 
0.000 
 % within 
Serum 
cotinine  
level in ng/dl 
100.0% .0% 100.0% 
 % within 
Group 
80.0% .0% 40.0% 
3-5 Count 3 0 3 
 % within 
Serum 
cotinine  
level in ng/dl 
100.0% .0% 100.0% 
 % within 
Group 
20.0% .0% 10.0% 
5-50 Count 0 6 6 
 % within 
Serum 
cotinine  
level in ng/dl 
.0% 100.0% 100.0% 
 % within 
Group 
.0% 40.0% 20.0% 
Above 50 Count 0 9 9 
 % within 
Serum 
cotinine  
level in ng/dl 
.0% 100.0% 100.0% 
 % within 
Group 
.0% 60.0% 30.0% 
Total Count 15 15 30 
% within 
Serum 
cotinine  
level in ng/dl 
50.0% 50.0% 100.0% 
% within 
Group 
100.0% 100.0% 100.0% 
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Table 7: Saliva cotinine level in control group 
 
Saliva cotinine 
level in ng/dl Frequency Percent 
Below 3 13 86.7 
3-5 2 13.3 
Total 15 100.0 
 
 
 
Table 8: Saliva cotinine level in study group 
Saliva cotinine 
level in ng/dl Frequency Percent 
5-50 7 46.7 
Above 50 8 53.3 
Total 15 100.0 
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Table 9: Saliva cotinine level in control and study groups 
Saliva 
cotinine level 
in ng/dl 
 Group Total P. Value 
 Non-Smokers Smokers  
 
Below 3 Count 13 0 13 
0.000 
 % within 
Saliva 
cotinine level 
in ng/dl 
100.0% .0% 100.0% 
 % within 
Group 
86.7% .0% 43.3% 
3-5 Count 2 0 2 
 % within 
Saliva 
cotinine level 
in ng/dl 
100.0% .0% 100.0% 
 % within 
Group 
13.3% .0% 6.7% 
5-50 Count 0 7 7 
 % within 
Saliva 
cotinine level 
in ng/dl 
.0% 100.0% 100.0% 
 % within 
Group 
.0% 46.7% 23.3% 
Above 50 Count 0 8 8 
 % within 
Saliva 
cotinine level 
in ng/dl 
.0% 100.0% 100.0% 
 % within 
Group 
.0% 53.3% 26.7% 
Total Count 15 15 30 
% within 
Saliva 
cotinine level 
in ng/dl 
50.0% 50.0% 100.0% 
% within 
Group 
100.0% 100.0% 100.0% 
 Tables and Graphs  
 
 
62 
 
Table 10: Distribution of study group subjects according to number of 
cigarettes smoked per day 
No. of cig/day 
 Frequency Percent 
1-10 10 66.7 
11-30 5 33.3 
Total 15 100.0 
 
 
Table 11: Distribution of study group subjects according to number of 
years of smoking 
No. of yrs. of 
smoking Frequency Percent 
Below 10 12 80.0 
11-40 3 20.0 
Total 15 100.0 
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Table 12: Correlation between age in year and Serum cotinine level in 
control group 
Age in years 
Serum cotinine  
level in ng/dl Total 
P. Value 
Below 3 3-5  
0.243 
Less than 30 
Count 4 0 4 
% within Age 
in years 
100.0% .0% 100.0% 
% within 
Serum cotinine  
level in ng/dl 
33.3% .0% 26.7% 
More than 30 
 
Count 
8 3 11 
% within Age 
in years 
72.7% 27.3% 100.0% 
% within 
Serum cotinine  
level in ng/dl 
66.7% 100.0% 73.3% 
Total 
Count 12 3 15 
% within Age 
in years 
80.0% 20.0% 100.0% 
% within 
Serum cotinine  
level in ng/dl 
100.0% 100.0% 100.0% 
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Table 13: Correlation between age in year and saliva cotinine level in 
control group 
Age in years 
Saliva cotinine level 
in ng/dl Total 
P. Value 
Below 3 3-5   
Less than 30 
Count 3 1 4 
0.423 
% within 
Age in years 
75.0% 25.0% 100.0% 
% within 
Saliva 
cotinine 
level in 
ng/dl 
23.1% 50.0% 26.7% 
More than 
30 
Count 10 1 11 
% within 
Age in years 
90.9% 9.1% 100.0% 
% within 
Saliva 
cotinine 
level in 
ng/dl 
76.9% 50.0% 73.3% 
Total 
Count 13 2 15 
% within 
Age in years 
86.7% 13.3% 100.0% 
% within 
Saliva 
cotinine 
level in 
ng/dl 
100.0% 100.0% 100.0% 
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Table 14: Correlation between Serum and saliva cotinine levels in        
control group 
Serum cotinine  level in 
ng/dl 
Saliva cotinine level 
in ng/dl Total 
P. Value 
Below 3 3-5   
Below 3 
Count 11 1 12 
0.255 
% within 
Serum 
cotinine  
level in 
ng/dl 
91.7% 8.3% 100.0% 
% within 
Saliva 
cotinine 
level in 
ng/dl 
84.6% 50.0% 80.0% 
3-5 
Count 2 1 3 
% within 
Serum 
cotinine  
level in 
ng/dl 
66.7% 33.3% 100.0% 
% within 
Saliva 
cotinine 
level in 
ng/dl 
15.4% 50.0% 20.0% 
Total 
Count 13 2 15 
% within 
Serum 
cotinine  
level in 
ng/dl 
86.7% 13.3% 100.0% 
% within 
Saliva 
cotinine 
level in 
ng/dl 
100.0% 100.0% 100.0% 
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Table 15: Correlation between Serum and saliva cotinine levels in           
study group 
Serum cotinine level in 
ng/dl 
Saliva cotinine level 
in ng/dl Total 
P.Value 
5-50 
Above 
50  
 
5-50 
Count 5 1 6 
0.020 
% within 
Serum 
cotinine  
level in 
ng/dl 
83.3% 16.7% 100.0% 
% within 
Saliva 
cotinine 
level in 
ng/dl 
71.4% 12.5% 40.0% 
Above 50 
Count 2 7 9 
% within 
Serum 
cotinine 
level in 
ng/dl 
22.2% 77.8% 100.0% 
% within 
Saliva 
cotinine 
level in 
ng/dl 
28.6% 87.5% 60.0% 
Total 
Count 7 8 15 
% within 
serum 
cotinine 
level in 
ng/dl 
46.7% 53.3% 100.0% 
% within 
Saliva 
cotinine 
level in 
ng/dl 
100.0% 100.0% 100.0% 
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Table 16: Correlation between age in year and Serum cotinine level in 
study group 
Age in years 
Serum cotinine 
level in ng/dl Total 
P. Value 
5-50 
Above 
50  
 
Less than 30 
Count 5 5 10 
0.264 
% within 
Age in years 
50.0% 50.0% 100.0% 
% within 
Serum 
cotinine  
level in 
ng/dl 
83.3% 55.6% 66.7% 
More than 
30 
Count 1 4 5 
% within 
Age in years 
20.0% 80.0% 100.0% 
% within 
serum 
cotinine 
level in 
ng/dl 
16.7% 44.4% 33.3% 
Total 
Count 6 9 15 
% within 
Age in years 
40.0% 60.0% 100.0% 
% within 
Serum 
cotinine 
level in 
ng/dl 
100.0% 100.0% 100.0% 
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Tables 17: Correlation between age in year and saliva cotinine level in 
study group 
Age in years 
Saliva cotinine level 
in ng/dl Total 
P. Value 
5-50 
Above 
50  
 
Less than 30 
Count 7 3 10 
0.010 
% within 
Age in years 
70.0% 30.0% 100.0% 
% within 
Saliva 
cotinine 
level in 
ng/dl 
100.0% 37.5% 66.7% 
More than 
30 
Count 0 5 5 
% within 
Age in years 
.0% 100.0% 100.0% 
% within 
Saliva 
cotinine 
level in 
ng/dl 
.0% 62.5% 33.3% 
Total 
Count 7 8 15 
% within 
Age in years 
46.7% 53.3% 100.0% 
% within 
Saliva 
cotinine 
level in 
ng/dl 
100.0% 100.0% 100.0% 
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Table 18: Correlation between number of cigarettes Smoked per day and 
Serum cotinine level in study group 
No . of cig/day 
Serum cotinine  
level in ng/dl Total 
P.Value 
5-50 
Above 
50  
 
1-10 
Count 6 4 10 
0.025 
% within No 
. of cig/day 
60.0% 40.0% 100.0% 
% within 
serum 
cotinine 
level in ng/dl 
100.0% 44.4% 66.7% 
11-30 
Count 0 5 5 
% within No 
. of cig/day 
.0% 100.0% 100.0% 
% within 
serum 
cotinine  
level in ng/dl 
.0% 55.6% 33.3% 
Total 
Count 6 9 15 
% within No 
. of cig/day 
40.0% 60.0% 100.0% 
% within 
Serum 
cotinine  
level in ng/dl 
100.0% 100.0% 100.0% 
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Table 19: Correlation between number of cigarettes smoked per day and 
saliva cotinine level in study group 
No . of cig/day 
Saliva cotinine level 
in ng/dl Total 
P. Value 
5-50 
Above 
50  
 
1-10 
Count 6 4 10 
0.143 
% within No 
. of cig/day 
60.0% 40.0% 100.0% 
% within 
Saliva 
cotinine 
level in ng/dl 
85.7% 50.0% 66.7% 
11-30 
Count 1 4 5 
% within No 
. of cig/day 
20.0% 80.0% 100.0% 
% within 
Saliva 
cotinine 
level in ng/dl 
14.3% 50.0% 33.3% 
Total 
Count 7 8 15 
% within No 
. of cig/day 
46.7% 53.3% 100.0% 
% within 
Saliva 
cotinine 
level in ng/dl 
100.0% 100.0% 100.0% 
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Table 20: Correlation between number of years of smoking and Serum 
cotinine level in study group 
No. of yrs. of smoking 
Serum cotinine 
level in ng/dl Total 
P. Value 
5-50 
Above 
50  
 
Below 10 
Count 5 7 12  
% within 
No. of yrs. 
of smoking 
41.7% 58.3% 100.0% 
0.792 
% within 
Serum 
cotinine 
level in 
ng/dl 
83.3% 77.8% 80.0% 
11-40 
Count 1 2 3 
% within 
No. of yrs. 
of smoking 
33.3% 66.7% 100.0% 
% within 
Serum 
cotinine 
level in 
ng/dl 
16.7% 22.2% 20.0% 
Total 
Count 6 9 15 
% within 
No. of yrs. 
of smoking 
40.0% 60.0% 100.0% 
% within 
serum 
cotinine 
level in 
ng/dl 
100.0% 100.0% 100.0% 
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Table 21: Correlation between number of years of smoking and saliva 
cotinine level in study group 
No. of yrs. of smoking 
Saliva cotinine level 
in ng/dl Total 
P. Value 
5-50 
Above 
50  
 
Below 10 
Count 7 5 12 
0.070 
% within 
No. of yrs. 
of smoking 
58.3% 41.7% 100.0% 
% within 
Saliva 
cotinine 
level in 
ng/dl 
100.0% 62.5% 80.0% 
11-40 
Count 0 3 3 
% within 
No. of yrs. 
of smoking 
.0% 100.0% 100.0% 
% within 
Saliva 
cotinine 
level in 
ng/dl 
.0% 37.5% 20.0% 
Total 
Count 7 8 15 
% within 
No. of yrs. 
of smoking 
46.7% 53.3% 100.0% 
% within 
Saliva 
cotinine 
level in 
ng/dl 
100.0% 100.0% 100.0% 
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Grahp-1: Age wise distribution of Subjects in Control group 
 
 
 
 
Graph-2: Age wise distribution of Subjects in study group 
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Graph-3: Age wise distribution of Subjects in control and study groups 
 
 
 
Graph-4: Serum cotinine level in control group 
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Graph-5: Serum cotinine level in study group  
 
 
 
 
Graph-6: Serum cotinine level in control and study groups 
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Graph-7: Saliva cotinine level in control group 
 
 
 
Graph-8: Saliva cotinine level in study group 
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Graph-9: Saliva cotinine level in control and study  groups
 
 
 
Graph-10: Distribution of study group subjects according to number of 
cigarettes smoked per day 
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Graph-11: Distribution of study group subjects according to number of 
years of smoking 
 
 
Graph-12: Correlation between age in year and Serum cotinine level in 
control group 
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Graph-13: Correlation between age in year and saliva cotinine level in 
control group 
 
Graph-14: Correlation between Serum and saliva cotinine levels in 
control groups 
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Graph-15: correlation between Serum and saliva cotinine levels in        
study group 
 
 
Graph-16: Correlation between age in year and Serum cotinine level in 
study group 
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Graph-17: Correlation between age in year and saliva cotinine level in 
study group 
 
 
Graph-18: Correlation between number of cigarettes Smoked per day  
and Serum cotinine level in study group 
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Graph-19: Correlation between number of cigarettes smoked per day and 
saliva cotinine level in study group  
 
 
 
Graph-20: Correlation between number of years of smoking and Serum 
cotinine level in study group
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Graph-21: Correlation between number of years of smoking and saliva 
cotinine level in study group 
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The World Health Organization predicts that tobacco deaths in India 
may exceed 1.5 million annually by 2020.
3 
Cigarette smoke is a complex mixture of components, such as carbon 
monoxide (CO), hydrogen cyanide (HCN) and nitrogen oxides, which are 
gases. Others, such as formaldehyde, acrolein, benzene and certain N-
nitrosamines, are volatile chemicals contained in the liquid- vapor portion of 
the smoke aerosol.  Still others, such as nicotine, phenol, polyaromatic 
hydrocarbons (PAHs), and certain tobacco-specific nitrosamines (TSNAs), are 
contained in the submicron-sized solid particles that are suspended in cigarette 
smoke.  
In view of this chemical complexity, cigarette smoke has multiple, 
highly diverse effects on human health.  It is not unexpected that multiple 
chemicals in cigarette smoke can contribute to any single adverse health 
effect.
10 
The adverse effects of smoking are not necessarily limited to active 
users of tobacco products. In recent years concern about health risks 
experienced by non smokers who are involuntarily exposed to tobacco smoke 
through passive smoking. ETS is a similar, but not identical to mainstream 
smoke inhaled during active smoking and many of hazardous substances 
known to be present in mainstream smoke are also present in ETS. In fact 
because of difference in combustion and aging some of the substances are 
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actually prevalent in ETS than in mainstream smoke. Strong evidence 
indicates that ETS represents a serious and substantial public health problem.
44 
Cotinine the major proximate metabolite of nicotine, has been widely 
used as a biomarker of exposure to tobacco and both active and second hand 
tobacco.
45 
The present study is a case control study conducted by Ragas Dental 
College and Hospital, Chennai and Sri Ramachandra Medical College, Porur, 
Chennai. It was devised to estimate and compare the serum and saliva cotinine 
levels in smokers and non-smokers with high profile liquid chromatography. 
The study was conducted between March 2012 and August 2012 with 15 
smokers and 15 non-smokers.  
Aim of the study is to estimate and compare cotinine level in smokers 
and Non- smokers in saliva and serum. 
According to the most recent Government of India’s National sample 
survey data, there are 184 million tobacco consumers in India. About 60% are 
tobacco smokers. 
In our study, among the 30 male subjects where 15 of them are tobacco 
smokers, the age chosen was 18 years and above. Among the control group of 
15 subjects 4 (26.7%) were in age group of less than 30 years and 11 (73.3%) 
were in age group of more than 30 years. This is in accordance with Rani, 
Bonu, Jha, et al
2  
who studied prevalence and predictors of smoking in a 
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national cross sectional household survey of  315 598 individuals 15 years or 
older in National Family Health Survey-2 (1998–99).Hence the age of our 
control group have been matched in accordance with the studies mentioned.
2 
In our study among the 30 male subjects where 15 of them are tobacco 
smokers, the minimum age obtained was 20 years and maximum of 75 years. 
Among the study group of 15 subjects 10 (66.7%) subjects were in age group 
of less than 30 years and 5 (33.3%) subjects were in age group of more than 
30 years. This is in accordance with Rani, Bonu, Jha, et al
2 
who studied 
prevalence and predictors of smoking in a national cross sectional household 
survey of 315 598 individuals 15 years or older in National Family Health 
Survey-2 (1998–99).Their findings show that thirty per cent of the population 
15 years or older smoke cigarrete, Their study also revealed that compared to 
the younger population (15–24 years), the older population (25+years) had a 
greater likelihood of smoking tobacco. The prevalence of tobacco 
consumption increased up to the age of 50 years. 
In our control group of 15 subjects we obtained serum cotinine levels 
values between 0 and 5ng/dl. Serum cotinine levels obtained were below 3 in 
12 (80%) subjects and between 3-5 in 3 (20%) of the subjects. Our results are 
in accordance with study by Jarvis et al
24
 who studied 211 non smokers and 
obtained mean values of 2.3ng/dl. The Serum cotinine level in the study group 
was divided in to levels below 5-50ng/dl and above 50ng/dl. Among 15 
subjects Serum cotinine levels obtained were 5-50 in 6 (40%) subjects and 
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above 50 in 9 (60%) of the subjects. Jarvis et al
34
 who studied 211 smokers 
and obtained mean values of 164 ng/dl. 
Their study stated that the concentration of cotinine, whether measured 
in Serum. saliva.or urine, was the best indicator of smoking. with sensitivity of 
96-97 per cent and specificity of 99-100 per cent. The results of their study 
concluded that the concentration of certain biochemical markers of smoke 
intake in the body can give a categorization of smoking status which is 
substantially more accurate than self report. Though their study was based on 
Gas chromatography method, the values obtained are similar to our study. 
Machacek and Jiang et al
35
 measured plasma cotinine levels in non-
smokers by Reversed- phase paired ion liquid chromatography. The mean               
(±SD) concentration of cotinine in plasma of 31 nonsmokers, obtained was 2.1 
±1.6 µg/L (range, 0-7.9 g/L) which is higher than the values obtained in our 
study. The discrepancy in the values maybe due to the difference in the 
methodology.  
In our study group of 15 subjects serum cotinine levels were grouped 
in to values between 5 – 50ng/dl and more than 50ng/dl. Serum cotinine levels 
obtained were 5 – 50ng/dl in 6 (40%) subjects and above 50ng/dl in 9 (60%) 
of the subjects. 
Machacek and Jiang et al
35
 measured plasma cotinine levels in 
smokers by Reversed- phase paired ion liquid chromatography. The mean 
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(±SD) concentration of cotinine in plasma of 10 smokers, obtained was 
150µg/l. which is higher than the values obtained in our study. The 
discrepancy in the values maybe due to the difference in the methodology and 
the sample size. 
Our serum cotinine levels are not in accordance with, Jarvis et al 
1987
24
 who studied 211 patients and obtained values of 330+/- 190ng/dl. The 
discrepancy in the values may be due to the population studied, methodology 
used and smaller sample size. 
On comparison of Serum cotinine levels in control and study group of 
30 subjects 15 subjects in 12 (80%) of the control group subjects the Serum 
cotinine levels obtained were below 3 and 3 (20%) of the subjects showed 
values in the range of 3- 5 ng/dl. And none (0%) of the study group subjects 
showed values below 3 and between 3 – 5.  Among 15 subjects in 12 (80%) of 
the study group subjects the Serum cotinine levels obtained were 5 – 50 in 6 
(40%) subjects  and above 50 in 9 (60%) of the subjects. And none (0%) of the 
study group subjects showed values above 50 and between 3 – 5. The p value 
obtained is 0.000 which is < 0.001 and is highly significant. 
Among our control group of 15 subjects who are non-smokers saliva 
cotinine levels obtained were 0 – 5 ng/dl. We obtained values below 3 in 13 
(86.7%) subjects and between 3 – 5 ng/din 2 (13.3%) of the subjects. This 
value is in accordance with, Jarvis et al 1987
27
 who studied 211 patients and 
obtained values of 1.7 ng/dl. 
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Our salivary cotinine levels in non smokers are also in accordance with 
Coutlas et al
37
 who obtained values of 1.6 +/- 2.8 ng/dl by Radio-immuno 
assay method which is in accordance with our study. This comparison also 
indicates that the saliva cotinine levels in non-smokers are within the range 
mentioned above irrespective of the methodology used. 
Our results are in accordance with study conducted by Abrams et al
36
 
who obtained value of 0.3+/- 1.6 ng/dl. Their study concluded that and all of 
the nonsmokers had levels of less than 10 ng/ml. 
Our study revealed zero saliva cotinine values in five subjects out of 15 
control group subjects with rest of subjects showing values within 5ng/dl. 
Michael A Wall et al
39 
studied 19 subjects in age range of 24- 66 years by gas 
liquid chromatography where the samples were categorized into non–smokers, 
passive and active smokers and found only a minority of non- smokers had 
detectable cotinine levels in their serum (n=1) or saliva (n=1).This discrepancy 
in the results are due to the fact that our control group sample was not 
categorized into passive smokers and non-smokers. Moreover all samples in 
Michael A Wall study were taken in early morning before going to work and 
hence they would not have been exposed to environmental tobacco exposure 
whereas samples in our study were taken between mid - morning and 
afternoon. 
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Our values are also in accordance with Ettar et al
42  
 who analysed 97 
nonsmokers for cotinine concentration in saliva and obtained a concentration 
of 2.4ng/dl.  
In our study group of 15 subjects saliva cotinine levels obtained were 
grouped in the range of 5 – 50 ng/dland above 50 ng/dl. saliva cotinine levels 
obtained were 5 – 50ng/dl in 7 (46.7%) subjects and above 50 ng/dlin 8 
(53.3%) of the subjects. 
Coutlas et al
37
 also obtained salivary Cotinine values of 296 +/- 208 
ng/dl in smokers by Radio-immuno Assay method which is in accordance with 
our study. This comparison also indicates that the saliva cotinine levels in 
smokers are within the range mentioned above irrespective of the 
methodology used.  
 Our values are also in accordance with Ettar et al
42
 who analysed 207 
smokers for cotinine concentration in saliva and obtained a concentration of 
113ng/dl. 
Our results are not in accordance with study conducted by Abrams et 
al
36
 who obtained value of 348 +/- 195.4 ng/dl. Variation in results may be due 
to methodology used and population studied.  
.  
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On comparison of saliva cotinine levels in control and study group of 
15 subjects 13 (86.7%) of the control group subjects the plasma saliva levels 
obtained were below 3 and 2 (13.3%) of the subjects showed values in the 
range of 3- 5 ng/dl. And none (0%)  of the study group subjects showed values 
below 3 and between 3 – 5.  Among 15 subjects in 7(46.7%) of the study 
group subjects the saliva cotinine levels obtained were 5 – 50 and above 50 in 
8 (53.3%) of the subjects. And none (0%) of the study group subjects showed 
values 5 - 50 and above 50. The p value obtained is 0.000 which is < 0.001 
and is highly significant. 
On distribution of 15 study group subjects according to number of 
cigarettes consumed per day 10 (66.7%) of them consumed 1 – 10 cigarettes 
per day and 5 (33.3%) of them consumed 11 – 30 per day.  On distribution of 
15 study group subjects according to number of years of smoking 12 (80%) of 
them were smoking for less than 10 years and 3 (20%) of them smoked in the 
range of 11 – 40 years.   
In our study we have obtained insignificant p values of > 0.05 on 
correlating age with serum and saliva cotinine levels in control group and 
positive correlation with a significant p value of < 0.05 was obtained on 
correlating age and saliva cotinine level and number of cigarettes consumed 
per day and serum cotinine level in study group. We obtained insignificant p 
value of  > 0.05 on correlating serum and saliva cotinine levels in control 
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group We have obtained positive correlation with a significant p value of                  
< 0.05 on correlating Serum and saliva cotinine levels in study group. 
The correlation between number of years of smoking and serum and 
salivary cotinine levels were insignificant with a p value of > 0.05. This can be 
attributed to smaller sample size, variation in time of sampling, assessment 
using single sample and variation in individual circadian rhythm. 
Further studies with modifications in above parameters would 
contribute to better results which would help us to establish saliva as effective 
diagnostic tool in estimation of cotinine levels in smokers for further 
management. 
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 The present study titled Estimation of cotinine level in the saliva, 
serum  in smokers and non-smokers was conducted  between March 2012 and 
August 2012 by Ragas Dental College and Hospital in Ramachandra Medical 
College and Research Institute, Chennai to estimate cotinine levels in saliva 
and serum of smokers and nonsmokers using high profile  liquid 
chromatography method. 
 The study group comprised of a total number of 30 patients. Out of 30 
subjects 15 were non smokers and 15 of them were smokers. Informed consent 
was taken from all subjects before including them in the study. Participants 
with systemic diseases and those who are currently not under any medication 
were excluded from the study. 
 For the determination of the cotinine concentration, the serum sample 
(0.5 ml) was alkalinized by 25 ml of 10 M NaOH and extracted with 4 ml of 
dichloromethane by shaking for 10 min. The organic fraction was evaporated 
with a vacuum evaporator at 408C without the addition of conc. HCl. 
 The residue was redissolved in 100 ml of the mobile phase and then an 
80 ml portion of the sample was subjected to HPLC. High-performance liquid 
chromatography Chromatography was performed using an L-7100 pump 
(Hitachi, Tokyo, Japan), an L-7400 UV detector (Hitachi), an L-7200 
autosampler (Hitachi), an L-7500 integrator (Hitachi), and an 865-CO column 
oven (Jasco, Tokyo, Japan). The ﬂow-rate was 1.0 ml /min and the column 
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temperature was 358C. The eluent was monitored at 260 nm with a noise-base 
clean Uni-3 (Union, Gunma, Japan. 
The study documents the following data 
 Age chosen in our study was 18 years and above. Among the control 
group of 15 subjects, the mean age obtained is 34 years with a standard 
deviation of 19.13 and among the study group of 15 subjects the mean 
age obtained is 44 years with a standard deviation of 15.65. 
 In control group of 15 subjects, serum cotinine levels obtained were 
below 3 in 12 (80%) subjects and between 3–5 in 3 (20%) of the 
subjects. 
 In study group of 15 subjects, serum cotinine levels obtained were                  
5 - 50 in 6 (40%) subjects and above 50 in 9 (60%) of the subjects. 
 In control group of 15 subjects, saliva cotinine levels obtained were 
below 3 in 13 (86.7%) subjects and between 3 – 5 in 2 (13.3%) of the 
subjects. 
 In study group of 15 subjects, saliva cotinine levels obtained were             
5 - 50 in 7 (46.7%) subjects and above 50 in 8 (53.3%) of the subjects. 
 Comparison of serum and saliva cotinine levels in control and study 
groups was highly significant with a p value of < 0.001. 
 Among 15 study group subjects, 10 (66.7%) of them consumed 1 – 10 
cigarettes per day and 5 (33.3%) of them consumed 11 – 30 per day.   
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 Among 15 study group subjects, 12 (80%) of them were smoking for 
less than 10 years and 3 (20%) of them smoked in the range of 11 – 40 
years.   
 We obtained insignificant correlations between age and serum cotinine 
levels in both control and study group. 
 We obtained insignificant correlation between age and saliva cotinine 
level in control group and positive correlations between age and saliva 
cotinine level in study group.  
 We obtained insignificant correlation between serum and saliva 
cotinine levels in control group and significant correlation between 
serum and saliva cotinine levels in study group. 
 We obtained significant correlation between number of cigarettes 
consumed per day and serum level in study group. 
 We obtained insignificant correlation between number of cigarettes 
consumed per day and saliva cotinine level in study group. 
 We obtained insignificant correlation between number of years of 
smoking and serum and saliva cotinine levels in study group. 
 To conclude our study shows highly significant difference between 
serum and saliva cotinine levels between smokers and non smokers. Our study 
shows that Measurement of cotinine levels can provide a sensitive estimate of 
tobacco smoke exposure. 
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 Data available in literature using HPLC method alone are scarce to 
arrive at conclusive results. For the purpose of developing epidemiologic 
studies, comparative data on relative sensitivities of cotinine measurements in 
serum and saliva with bigger sample size and in different population are 
required.  
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MASTER CHART 
SMOKERS – STUDY GROUP 
S.No. Name Age Sex 
No. of 
cig/day 
No. of 
yrs. of 
smoking 
plasma 
level in 
ng/dl 
saliva 
level 
in 
ng/dl 
1 Meeran 72 M 20 40 183.6 69.7 
2 Xavier  24 M 15 7 127.1 41.9 
3 Ranjith  24 M 6 4 50.6 58.2 
4 Sekar 26 M 30 15 76.4 77.3 
5 Aravind 24 M 10 5 175.4 39 
6 Dayalan 27 M 20 4 115.5 69.4 
7 Dheeraj 23 M 4 5 49.1 25.8 
8 Abraham 23 M 5 4 43.9 27 
9 Peter 24 M 3 4 24.78 40.14 
10 Thambaiya 85 M 8 30 20.7 67.9 
11 Arumugam 42 M 10 10 76.8 97.8 
12 Muthukumar 24 M 5 4 35.1 6.5 
13 Sundar 22 M 4 3 46.9 25.5 
14 Selvamani 33 M 5 6 80 84.7 
15 Gajendran 38 M 15 7 114.3 80.2 
        
Non Smokers - Control Group 
1 Srinivasan 42 M 
  
1.09 0.9 
2 Parthiban 36 M 
  
2.83 2.06 
3 Joeraman 25 M 
  
0.09 0.1 
4 Pearlcid 24 M 
  
2 4 
5 Munirammaiya 55 M 
  
3.83 1.6 
6 Narasimman 63 M 
  
0.06 1.02 
7 Parthiban  35 M 
  
0 0.1 
8 Radhakrishnan 65 M 
  
3.5 0.001 
9 Rajendran 41 M 
  
2.4 2.85 
10 Devaraj 52 M  
 
0 0 
11 Kondaiya 65 M 
  
0 0.01 
12 Michel 65 M 
  
0 0 
13 Velrajan 29 M 
  
0.02 1 
14 Lakshmanan 40 M 
  
4 3.2 
15 Gnanamurthi 24 M 
  
0 0 
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RAGAS DENTAL COLLEGE AND HOSPITAL 
Department of Oral Medicine, Diagnosis and Radiology 
CASE SHEET PROFOMA 
Estimation of cotinine level in the serum and saliva in active 
smokers and non-smokers 
 
A] General Information 
 DATE:                                 S.NO.                            OP. NO. 
1. Name: 
2. Age: 
3. Sex:     a. Male    b. Female 
4. Occupation: 
a. Unemployed 
b. Professional 
c .Administration 
d. Trade/Business 
e. Student 
5. Address: 
 
 Annexure II  
 
 
106 
 
6. Income: 
 a. <Rs.1000/month   b. > Rs.1000-5000/month   c.>Rs.5000 /month 
B] Past Dental History: 
C]   Habit 
 Smoking:   a) Type 
 b) Duration 
     c) Frequency 
D] Intra oral Examination 
Decay: 
Missing: 
Filled: 
Tobacco stains:  
E] Investigations 
 High profile liquid chromatography of 
Serum sample 
Saliva sample 
F] Results 
Serum cotinine level 
Saliva cotinine level 
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CONSENT LETTER 
 
I                                              , the under signed hereby give my 
consent to estimate and compare cotinine level in serum and saliva in smokers 
and non- smokers by high profile liquid chromatography by Dr. S. Parthiban, 
under the guidance of Dr.S. Kailasam MDS, Professor and Head of 
Department of Oral medicine Diagnosis and Radiology, Ragas dental college 
and Hospital. Chennai. I have been informed and explained about the 
evaluation procedure, risks involved and likelihood of successes. I also 
understand and accept this as part of study protocol, thereby voluntarily, 
unconditionally freely give my consent without any fear or pressure in 
mentally sound, conscious state to participate in the study. 
 
Witness/Representative                                        Patient Signature 
 
(if any)                                                                         Date: 
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Xg;g[jy; gotk; 
------------------------  vd;fpd;w ehd;/ brd;id uhfh!; gy; 
kUj;Jtf; fy;Y}hp kw;Wk; kUj;Jtkidapd; tha; kUj;Jtk; 
kw;Wk; CLfjph; Jiwapy; nguhrphpah; kU. S ifyh!k; B.Sc, 
M.D.S., mth;fspd; nkw;ghh;itapy;/ KJepiy (M.D.S) gl;lg;gog;g[ 
gapYk; kU.r.ghh;j;jpgd; mth;fs; nkw;bfhs;Sk; “g[ifg;gpof;Fk; 
gHf;fk; cs;nshh; kw;Wk; g[ifg;gpof;Fk; gHf;fk; my;yhjth;fs; 
Mfpnahhpd; ckPH;ePh; kw;Wk; ,uj;j rPuj;jpy; nfhl;od; msit 
fz;lwpjy;” vd;fpd;w Muha;r;rpf;fhd ghpnrhjidfSf;F vd;id 
cl;gLj;Jtjw;F vdJ kdKte;j ghpg{uz rk;kjj;jpid 
mspf;fpnwd;. 
 
 
 
rhl;rpahsh;fs; :       ,g;gof;F 
 
 
